Hospital employment, pay on the rise across the board

Overall U.S. hospital employment hit 5,223,000 in March, rising 2.11% over the 5,115,000 recorded in March of 2018, according to the latest numbers from the Bureau of Labor Statistics.

For nonsupervisory positions, the March year-to-year figures are not yet in, but from Feb. 2018 to Feb. 2019, the lift was a similarly sturdy 1.86%—approximately 4.666 million workers then to 4.753 million now.

What’s more, the spike in hiring was accompanied by gains in wages.

Earnings for all hospital workers in Feb. 2019 averaged $33 per hour, or around $66,000 annually, compared with $32/hour ($64K annually) in Feb. 2018.

Nonsupervisory hospital employees enjoyed an increase to $32/hour in Feb. 2019, up from $31/hour ($62K per year) in Feb. 2018.

Meanwhile DataUSA, a non-government source of hospital workforce growth, composition and compensation, had the average age of hospital workers at 42.9 years in 2016, with males earning an average $90,493 and females $57,675.

DataUSA, which is maintained by Deloitte, MIT and Datawheel, also broke down the salary averages into full time vs. part time, finding that the former had an average annual salary of $71,437 while their part-time coworkers took home $35,868.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.